Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Completed Phase 1 Trials for Vorinostat (DB02546)

IndicationStatusPhase
DBCOND0029591 (Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00357305Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersTreatment